CODX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CODX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has short-term momentum but is already overbought, lacks supportive news or strong bullish signals, and the latest financials show improving revenue but still very weak profitability. I would not buy it at the current level.
CODX is in a short-term bullish move: MACD histogram is positive and expanding, and the price closed above the previous close. However, RSI_6 at 84.478 is strongly overbought, which signals the move may be stretched. Moving averages are converging, suggesting the trend is not yet cleanly established for a durable long-term breakout. Key levels: Pivot 1.707, R1 1.902, R2 2.022; the stock is trading near resistance rather than at a favorable entry point. The probability pattern also looks weak beyond the near term, with a 70% chance of -4.51% over the next month.
["Revenue in 2025/Q4 increased 76.74% YoY to 263,922", "MACD histogram is positive and expanding, showing current momentum", "Price closed higher on the session and is above the prior close"]
["RSI is 84.478, indicating the stock is overbought", "Net income remains deeply negative at -25,745,725", "Gross margin is still negative at -55.33", "No news in the recent week, so there is no fresh catalyst driving sustained demand", "Hedge funds are neutral and insiders are neutral, with no significant recent trading trends", "No recent congress trading data available", "No AI Stock Picker or SwingMax signal today", "Near-term pattern outlook is weak, with a projected -4.51% move over the next month"]
In 2025/Q4, CODX showed strong top-line improvement, with revenue up 76.74% YoY to 263,922, which is a positive growth trend. However, the company is still not profitable: net income was -25,745,725 and EPS was -13.67, though both losses improved year over year. The major concern is the gross margin, which fell to -55.33, showing the business still struggles with profitability despite higher sales.
No analyst rating or price target change data was provided, so there is no recent Wall Street consensus shift to report. Based on the available data, analysts' pros would likely focus on revenue growth and improving losses, while the cons are the still-negative margins, ongoing net losses, and lack of supportive news or insider/institutional buying.
